Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | +0.00% | -100.00% | +0.00% | +0.00% |
| Gross Profit Growth | -201.65% | +0.00% | -100.48% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | -132.06% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | -137.75% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | -131.22% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | -131.46% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | -132.18% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -12.80% | +0.80% | +0.54% | +0.30% | +17.42% |
| Weighted Average Shares Diluted Growth | -12.80% | +0.80% | -1.64% | +0.30% | +17.42% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | -123.46% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | -123.57% | +0.00% | +0.00% |
| Receivables Growth | +48.60% | -9.69% | -62.25% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +1.17% | +4.33% | -22.23% | -22.99% | +40.49% |
| Book Value per Share Growth | +18.50% | +6.13% | -22.12% | -23.13% | +22.29% |
| Debt Growth | -20.26% | -20.05% | -21.56% | -23.34% | -25.33% |
| R&D Expense Growth | -40.29% | -30.53% | -24.76% | -2.34% | +35.90% |
| SG&A Expenses Growth | -17.53% | -30.43% | -33.37% | -10.23% | -5.69% |